ArticleJournal of pharmacopuncture2025
Ameliorating Effect of Red Fruit (
Article in Journal of pharmacopuncture, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Diabetic peripheral neuropathy (DPN) is the most common cause of neuropathy worldwide, with oxidative and inflammatory being the pathways involved in the disease pathology. Red fruit ( Methods: Male Wistar rats were induced with 55 mg/kg streptozotocin (STZ) intraperitoneally. Rats with fasting blood glucose ≥ 200 mg/dL were assigned into groups treated with vehicle, pregabalin 30 mg/kg, and 0.3, 0.6, or 1.2 mL/kg RFO, respectively. The treatments were given for 3 weeks, six weeks after STZ induction. Neuropathic pain was evaluated by cold allodynia and thermal hyperalgesia tests. Histopathological changes of the pancreas and sciatic nerve were evaluated by the Gaussian adaptive threshold method. Feed and drinking intake, blood glucose levels, body weight, and sciatic nerve proinflammatory cytokines were also measured. Results: There were increases in blood glucose levels, feed and drink intake, levels of MDA, TNF-α, IL-6, NFκB, and iNOS; decrease in catalase level; and damage to the sciatic nerve in the vehicle-treated DPN rat model compared with normal rats (p < 0.05). Meanwhile, significant decrease in weight, number of pancreatic β cells, latency times for thermal hyperalgesia as well as cold allodynia were observed in this group of rats. RFO administration at 0.6 and 1.2 mL/kg significantly improved all of the measured indices, except for iNOS, where only decreasing trend was observed. Pregabalin did not affect blood glucose levels, body weight or pancreatic β cells but improved thermal hyperalgesia as well as cold allodynia, the sciatic nerve cell counts, TNF-α IL-6, NFκB, and iNOS levels. Conclusion: RFO improves DPN by neuroprotective effect through the involvement of the oxidative and neuroinflammatory pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.